Podcast Episodes
Back to Search
Pharmaceutical Executive Daily: Egetis Sells Priority Review Voucher for $190 Million
ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics as Egetis separately sells its priority review voucher for $190 million, Novartis e…
1 week, 6 days ago
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion…
2 weeks ago
Pharmaceutical Executive Daily: FDA Approves Voceryq
FDA grants accelerated approval to INOVIO’s Voceryq to reduce surgical burden in recurrent respiratory papillomatosis, Brox.AI’s Hamish Brocklebank o…
2 weeks, 2 days ago
States Take Center Stage in the Drug Pricing Fight
In this episode of the Pharmaceutical Executive podcast, Scott LaGanga, executive vice president of state advocacy at PhRMA, discusses the expanding…
2 weeks, 2 days ago
Pharmaceutical Executive Daily: Pathos AI Enters Collaboration with Bristol Myers Squibb
Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Brist…
3 weeks, 2 days ago
The Ron Lanton Report: A Conversation with Dr. Nadine Zawadzki
Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined …
3 weeks, 2 days ago
Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act
Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisiti…
3 weeks, 5 days ago
Building Biopharma Manufacturing for Speed, Scale, and Flexibility
Biopharma manufacturing today is being asked to move faster, accommodate increasingly complex modalities, and respond more readily to changing devel…
3 weeks, 5 days ago
Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition …
3 weeks, 6 days ago
Pharmaceutical Executive Daily: FDA Approves Hibsago
A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure th…
4 weeks ago